Familial partial lipodystrophy (FPLD) syndromes are rare diseases characterized by a limited capacity of peripheral fat to store triglycerides, which results in metabolic abnormalities including insulin resistance, hypertriglyceridemia, liver steatosis, and polycystic ovary syndrome ([@bib1]). Heterozygous frameshift variants in the *PLIN1* gene encoding perilipin-1 have been identified in six families ([@bib2]--[@bib4]), thereby defining the FPLD type 4 (FPLD4) subtype.

Perilipin-1 is a structural lipid droplet protein that facilitates triglyceride storage or initiates lipolysis, depending on the hormonal stimuli. We have shown that several FPLD4-associated *PLIN1* frameshift variants disrupt the ability of perilipin-1 to inhibit basal lipolysis in adipocytes ([@bib2], [@bib3], [@bib5]). However, the pathogenicity of other heterozygous *PLIN1* null variants, identified in patients referred for evaluation of maturity onset diabetes of the young, hyperinsulinemic hypoglycemia, or type 2 diabetes, has recently been questioned by Laver *et al.* ([@bib6]).

Since proper interpretation of *PLIN1* variants is crucial for genetic counseling, the aim of the present study was to determine the pathogenicity of *PLIN1* null variants in the light of the new genotype--phenotype data obtained in the largest series of patients with FPLD4 reported to date.

Subjects and Methods {#s6}
====================

Sequencing of a panel of lipodystrophy genes (*AGPAT2, AKT2, BSCL2, CAV1, CIDEC, LIPE, LMNA, PLIN1, POLD1, PPARG, PTRF,* and *ZMPSTE24*) was performed in 237 independent index cases, investigated in our French National Reference Network for Rare Diseases of Insulin Secretion and Insulin Sensitivity, for manifestations evocative of a lipodystrophic syndrome. Capture (SeqCap EZ enrichment protocol, Roche NimbleGen, Roche Sequencing, Pleasanton, CA) was followed by massively parallel sequencing on a MiSeq platform (Illumina Inc., San Diego, CA). The data were analyzed using the Sophia Genetics DDM pipeline^®^. *PLIN1* frameshift variants were confirmed by Sanger sequencing. Affected relatives were identified after familial investigations. Abdominal subcutaneous adipose tissue biopsy specimens were obtained from two patients. Western blot and histological analyses were performed as previously described ([@bib2]). All the subjects provided written informed consent in accordance with the legal procedures for molecular and histological investigations and publication of photographs. The Comité de Protection des Personnes Ile-de-France 5 (Paris, France) approved the present study.

Results {#s7}
=======

Molecular diagnosis {#s8}
-------------------

A heterozygous *PLIN1* frameshift variant was identified in four index cases and five affected relatives ([Fig. 1A](#fig1){ref-type="fig"}). Patients from family D and L carried the c.1191_1192del deletion, previously shown to be expressed as an abnormal p.(Val398Glyfs\*166) elongated form of perilipin-1, leading to constitutive activation of basal lipolysis ([@bib2], [@bib5]). In family E and C, we identified a 4bp-duplication in exon 8 (c.1202_1205dup), leading to the synthesis of a p.(Pro403Argfs\*164) mutant protein, whose expression in adipose tissue was confirmed by Western blot ([Fig. 2](#fig2){ref-type="fig"}). These variants were not found in public databases (Exome Aggregation Consortium, Genome Aggregation Database) and cosegregated with the disease within each family ([Fig. 1A](#fig1){ref-type="fig"}). In all patients, we did not find any other molecular defect in known lipodystrophy genes.

![(A) Molecular and clinical investigations of patients with heterozygous *PLIN1* null variants. *Arrows* indicate index cases. Genealogical trees show a cosegregation of *PLIN1* variants with the disease phenotype. The nomenclature of *PLIN1* variants is based on the RefSeq accession numbers NM_002666.5 and NP_002657.3. (B) Morphotype of patient E-II2 with partial lipodystrophy and acromegaloid features. Subcutaneous lipoatrophy of the upper and lower limbs can be observed, with muscle hypertrophy (*arrows*). Compared with patients with FPLD type 2 (*LMNA*-linked FPLD), the neck is less broad, and the breast and subcutaneous abdominal fat are not affected by lipoatrophy. The acromegaloid features include face infiltration, a slightly enlarged nose, deep wrinkles, thick lips and hands, and enlarged feet.](jc.2019-00849f1){#fig1}

![Study of subcutaneous adipose tissue from patients. (A) Perilipin-1 expression in abdominal subcutaneous adipose tissue from patients E-II2 and E-I1 compared with controls and previously described patients with FPLD4 ([@bib2]). Western blot of whole cell extracts was performed using antibodies directed against the N-terminal and C-terminal parts of wild-type perilipin-1, as previously described ([@bib2]). The mutant isoform was recognized by the N-terminal antibody as an additional band (*arrow*) just above the 62-kD molecular weight (MW) marker, which was not detected by the C-terminal antibody. Tubulin (antibody T5168, Sigma-Aldrich, St. Quentin-Fallavier, France) was used as a loading control. (B) Consequences on perilipin-1 protein expression of FPLD4-associated *PLIN1* frameshift variants studied in (A). (C) Histological and immunohistological analyses of abdominal subcutaneous adipose tissue from patients E-I1 and E-II-2 compared with controls. Adipose tissue samples from patients displayed disorganized fat lobules of heterogeneous size, with increased fibrosis \[Sirius red (SR) staining, 16% to 35% of the total sample surface vs 0.2% to 3% in controls\], increased vascularization (density of CD34 staining, 0.13% to 0.44% in adipose lobules from patients vs 0.001% to 0.004% in controls), and increased macrophage infiltration with crown-like structures (assessed by CD163 and CD68 staining, density per 10^−5^ μm^2^: 1.9 to 2.2 and 3.6 to 4.3 in patients vs 0.0 and 0.0 to 0.01 in controls, respectively).](jc.2019-00849f2){#fig2}

Disease phenotype {#s9}
-----------------

The clinical and biological features of the nine investigated family members carrying a *PLIN1* variant recapitulated the FPLD4 cardinal signs ([@bib2]) (*i.e.,* lipoatrophy, muscular hypertrophy, facial acromegaloid features, insulin resistance-related ovarian dysfunction, and metabolic complications (*e.g.,* hyperinsulinemia or insulin-resistant diabetes, hypertriglyceridemia, liver steatosis) ([Table 1](#tbl1){ref-type="table"}). The index cases had initially been referred for ovarian hyperandrogenism with lipodystrophy (patient D-II3), suspicion of acromegaly (patients L and E-II2), or early-onset nonautoimmune diabetes (patient C-II1). In several individuals (patients D-I2, C-I2, C-II2), the disease manifestations were only detected after family studies.

###### 

Characteristics of Patients Investigated in the Present Study

  Characteristic                                 Family D                                                                       Family L                                                               Family E                                                               Family C                                                                   Mean ± SD                                                              Median (Range)                                                                                                                                                                                                                                                                                                                                     
  ---------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------- ---------------------------------
  Patient number                                 D-I2                                                                           D-II3[\*](#tblfn4){ref-type="table-fn"}                                L[\*](#tblfn4){ref-type="table-fn"}                                    E-I1                                                                       E-II2[\*](#tblfn4){ref-type="table-fn"}                                E-III1                                                                 C-I2                                                                                 C-II1[\*](#tblfn4){ref-type="table-fn"}                                               C-II2                                                                  NA                        NA
  Sex                                            Female                                                                         Female                                                                 Female                                                                 Male                                                                       Female                                                                 Male                                                                   Female                                                                               Female                                                                                Female                                                                 NA                        NA
  Age, y                                         54                                                                             24                                                                     67                                                                     69                                                                         40                                                                     17                                                                     41                                                                                   17                                                                                    13                                                                     38 ± 21.7                 40 (13--69)
  BMI, kg/m^2^                                   23                                                                             25.5                                                                   22.7                                                                   25.7                                                                       30.7                                                                   23.8                                                                   29.8                                                                                 25.4                                                                                  19.6                                                                   25.1 ± 3.5                25.4 (19.6--30.7)
  Origin                                         France                                                                         France                                                                 France                                                                 France                                                                     France                                                                 France                                                                 France                                                                               France                                                                                France                                                                                           
  Age at diagnosis, y                            54                                                                             15                                                                     40                                                                     58                                                                         38                                                                     17                                                                     41                                                                                   15                                                                                    13                                                                     32.3 ± 17.7               38 (13--58)
  Lipodystrophy                                  Android habitus; four limb lipoatrophy                                         Android habitus; four limb lipoatrophy                                 Generalized lipoatrophy                                                Four limb, gluteal and trunk lipoatrophy; cervicofacial fat accumulation   Lower limb and gluteal lipoatrophy                                     Mild lower limb, gluteal and trunk lipoatrophy                         Android habitus; four limb and gluteal lipoatrophy; cervicofacial fat accumulation   Android habitus; lower limb and gluteal lipoatrophy; cervicofacial fat accumulation   Mild lower limb lipoatrophy                                            NA                        NA
  Acromegaloid features                          Present                                                                        Present                                                                Present                                                                Absent                                                                     Present                                                                Present                                                                Present                                                                              Present                                                                               Absent                                                                 NA                        NA
  Muscular hypertrophy                           Present                                                                        Present                                                                Present                                                                Present                                                                    Present                                                                Present                                                                Present                                                                              Present                                                                               Not obvious                                                            NA                        NA
  Acanthosis nigricans                           Absent                                                                         Present                                                                Absent                                                                 Absent                                                                     Present                                                                Absent                                                                 Present                                                                              Present                                                                               Absent                                                                 NA                        NA
  Total fat (DEXA), %                            23.1                                                                           NA                                                                     12                                                                     16.4                                                                       21                                                                     13                                                                     NA                                                                                   NA                                                                                    NA                                                                     17.1 ± 4.9                16.4 (12--23.1)
  Serum leptin, ng/mL                            1.7                                                                            1.1                                                                    1.9                                                                    6.5                                                                        7.0                                                                    3.2                                                                    NA                                                                                   12                                                                                    NA                                                                     4.8 ± 3.9                 3.2 (1.1--12)
  Glucose tolerance                              Gestational diabetes at age 20, 23, and 30 y; permanent diabetes at age 34 y   Impaired glucose tolerance at age 15 y; diabetes at age 20 y           Diabetes diagnosed at age 40 y                                         Diabetes diagnosed at age 58 y                                             Gestational diabetes at age 30 y; permanent diabetes at age 38 y       Normal glucose tolerance with increased fasting insulin                Impaired fasting glucose; antecedent of gestational diabetes                         Diabetes diagnosed at age 15 y                                                        Normal fasting glucose with increased fasting insulin                  NA                        NA
  Serum fasting glucose/insulin, mmol/L/pmol/L   8/NA (insulin therapy); preserved C-peptide (1.2 nmol/L)                       6.1/402 at age 15 y with BMI 24 kg/m^2^                                3.9/NA (insulin therapy)                                               8.3/NA                                                                     7.4/112                                                                4.5/65.2                                                               6.1/456                                                                              7.2/NA (insulin therapy); high C-peptide (3.3 nmol/L)                                 4.6/257                                                                6.2 ± 1.6/258.4 ± 172.1   6.1 (3.9--8.3)/257 (65.2--456)
  HbA1c, %                                       8                                                                              5.8                                                                    7.1                                                                    7.1                                                                        6.5                                                                    4.9                                                                    5.6                                                                                  12.2                                                                                  5.4                                                                    7.0 ± 2.2                 6.5 (5.4--12.2)
  Triglycerides (≥2 mmol/L)                      Present                                                                        Present                                                                Present                                                                Present                                                                    Present from age 18 y                                                  Present                                                                Present                                                                              Present                                                                               Absent                                                                 NA                        NA
  Serum fasting triglycerides/HDL-C, mmol/L      2/1.17                                                                         3.4/0.55                                                               3.3/0.98                                                               4.7/1.0                                                                    5.7/0.82                                                               6.2/0.82                                                               6.4/0.57                                                                             6.1/NA                                                                                0.5/0.98                                                               4.3 ± 2.1/0.86 ± 0.22     4.7 (0.5--6.4)/0.9 (0.55--1.17)
  Liver steatosis                                Present                                                                        Present                                                                NA                                                                     NA                                                                         Present                                                                NA                                                                     NA                                                                                   Present                                                                               Present                                                                NA                        NA
  AST/ALT, mIU/L                                 18/29                                                                          50/78                                                                  45/63                                                                  22/38                                                                      24/23                                                                  19/10                                                                  30/56                                                                                171/216                                                                               36/36                                                                  46.1 ± 48.1/61 ± 61.8     30 (18--171)/38 (10--216)
  PCOS or hirsutism                              Hirsutism; oligomenorrhea                                                      PCOS                                                                   Absent                                                                 NA                                                                         Mild hirsutism                                                         NA                                                                     PCOS                                                                                 Oligomenorrhea                                                                        Absent                                                                 NA                        NA
  Glucose and lipid lowering therapy             Metformin, insulin (\>2 U/kg/d), statin                                        Metformin, iDPP4                                                       Metformin, insulin (\>3 U/kg/d)                                        Metformin, HS, GLP1R-A, insulin                                            Metformin, GLP1R-A, statin                                             None                                                                   None                                                                                 Metformin, GLP1R-A, insulin                                                           None                                                                   NA                        NA
  Other signs                                    Fatigue; unexplained recurrent vomiting                                        Becker nevus of the shoulder; muscle fatigability                      Hypertension; myocardial infarction and rhythm disturbances            None                                                                       Severe fatigue; hypertension                                           None                                                                   NA                                                                                   NA                                                                                    NA                                                                     NA                        NA
  *PLIN1* variant                                c.1191_1192del; p.(Val398Glyfs[\*](#tblfn4){ref-type="table-fn"}166)           c.1191_1192del; p.(Val398Glyfs[\*](#tblfn4){ref-type="table-fn"}166)   c.1191_1192del; p.(Val398Glyfs[\*](#tblfn4){ref-type="table-fn"}166)   c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)       c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)   c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)   c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)                 c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)                  c.1202_1205dup; p.(Pro403Argfs[\*](#tblfn4){ref-type="table-fn"}164)   NA                        NA

Patient numbers refer to those shown in [Fig. 1](#fig1){ref-type="fig"}; the nomenclature of *PLIN1* variants is based on RefSeq accession numbers NM_002666.5 and NP_002657.3.

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; DEXA, dual energy X-ray absorptiometry; GLP1R-A, GLP1R agonist; HDL-C, high-density lipoprotein cholesterol; HS, hypoglycemic sulfonamide; iDPP4, dipeptidyl peptidase-4 inhibitors; NA, not available/not applicable; PCOS, polycystic ovary syndrome.

Proband.

Lipoatrophy had mainly affected the trunk, limbs, and femorogluteal regions and was associated with muscular hypertrophy predominantly in the calves ([Fig. 1B](#fig1){ref-type="fig"}). Lipoatrophy could be mild, especially in young patients (patients E-III1 and C-II2). Cervicofacial fat accumulation was observed in three patients (patients E-I1, C-I2, and C-II1). Low serum leptin levels and a decrease in the total fat mass, as assessed by dual energy X-ray absorptiometry, were consistent with lipoatrophy. Abdominal subcutaneous adipose tissue, studied in patients E-I1 and E-II2, displayed disorganized fat lobules of heterogeneous size, with macrophage infiltrates, increased fibrosis, and increased vascularization, consistent with previous findings ([@bib2]) ([Fig. 2](#fig2){ref-type="fig"}). Seven patients showed a facial acromegaloid appearance with enlarged hands and feet. All investigated patients had presented with hyperinsulinemia or diabetes, frequently accompanied by acanthosis nigricans. Five of the seven women had polycystic ovary syndrome and/or hirsutism and oligomenorrhea. Hypertriglyceridemia was present in all investigated adult patients. No history of acute pancreatitis was reported. All examined patients had liver steatosis. Patient L-II1 had experienced major complications, including neuropathy, hypertension, and myocardial infarction with rhythm disturbances, which required the implantation of a cardioverter defibrillator.

Discussion {#s10}
==========

The increasing use of next generation sequencing in clinical practice highlights the need for accurate interpretation of variants. When large population exome data became available, the pathogenicity of several genes involved in Mendelian disorders was questioned ([@bib7]). This issue was recently raised for *PLIN1* by Laver *et al.* ([@bib6]). Because of the importance of early genetic counseling for appropriate disease management ([@bib1]), the clues arguing for and against a pathogenic effect of *PLIN1* null variants should be considered carefully ([Table 2](#tbl2){ref-type="table"}).

###### 

Criteria for Evaluating Pathogenicity of *PLIN1* Null Variants

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Criteria supporting evidence of pathogenicity**
   Absence of FPLD4-associated *PLIN1* variants in controls (Genome Aggregation Database, Exome Aggregation Consortium databases)
   Enrichment of *PLIN1* frameshift variants in cohorts of patients with FPLD compared with general population
   Segregation of FPLD4-associated *PLIN1* frameshift variants with the disease in eight families including 13 informative relatives
   Absence of other molecular explanations for the disease in all patients with FPLD4-associated *PLIN1* frameshift variants
   Homogeneity of the clinical and biological phenotype in patients with FPLD4-associated *PLIN1* frameshift variants
   Demonstration of the deleterious effect of three frameshift variants in several cellular models expressing the wild-type and mutated forms of the protein
  **Criteria supporting evidence of benign effect**
   Elevated frequency of *PLIN1* null variants in the general population
   Absence of manifestations evocative of FPLD in several individuals carrying *PLIN1* null variants
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

First, the allele frequency of *PLIN1* null variants in the general population, estimated at ∼4.10^−4^ in public databases, is higher than the prevalence of all forms of FPLD, estimated at ∼3.10^−6^ ([@bib8]). Even if FPLD remains underdiagnosed, this suggests that certain *PLIN1* null variants are not pathogenic. However, we observed a marked enrichment of *PLIN1* frameshift variants in patients with FPLD. The allele frequency of *PLIN1* frameshift variants was estimated at 1.9% in one of our previous studies (three heterozygotes among 78 independent patients with clinically ascertained FPLD) ([@bib2]) and at ∼0.8% in the present study (four positive probands for 237 tested patients).

Strikingly, the FPLD4-associated *PLIN1* variants cosegregated with the disease within the eight families available to date \[Gandotra *et al.* ([@bib2]), Kozusko *et al.* ([@bib3]), Chen *et al.* ([@bib4]), and the present study\]. If these variants were all polymorphisms, the probability to see such a segregation by chance in the 13 informative affected relatives would be extremely low \[(1/2)^13^; *i.e.,* 1.10^−4^).

The pathogenicity of *PLIN1* null variants was also questioned because the patients reported by Laver *et al.* ([@bib6]) did not have overt lipoatrophy. As acknowledged by the authors, it can be difficult to exclude the presence of lipodystrophy in young patients, and the lack of adipose tissue-focused examinations in large cohort studies hamper the recognition of subtle lipodystrophic morphotypes. In this regard, one study underlined that FPLD remains underdiagnosed and could affect \>3% of patients investigated for metabolic syndrome ([@bib9]). Accordingly, lipodystrophy was diagnosed *a posteriori* in several patients in the present study, owing to the familial investigations.

Four FPLD4-associated frameshift variants lead to the synthesis of aberrant perilipin-1 isoforms \[Gandotra *et al.* ([@bib2]), Kozusko *et al.* ([@bib3]), and the present study\]. Expression in adipocyte models of three of these mutant forms of perilipin-1 decreases the size of lipid droplets and increases basal lipolysis ([@bib2], [@bib3], [@bib5]). All but one FPLD4-associated *PLIN1* variants \[p.(Val398Glyfs\*166), p.(Tyr401Leufs\*165), p.(Pro403Argfs\*164), p.(Leu404Alafs\*158)\] alter the interaction domain of perilipin-1 with ABHD5 (amino acids 380 to 427). Consistently, the p.(Val398Glyfs\*166) and p.(Leu404Alafs\*158) mutants fail to interact with ABHD5, leading to constitutive activation of adipocyte triglyceride lipase ([@bib5]). The p.(Pro439Valfs\*125) mutant, which is located in the vicinity of this binding domain, fails to inhibit basal lipolysis by an alternate mechanism ([@bib3]). It would be interesting to determine the functional consequences of *PLIN1* null variants identified in the general population or in those with maturity onset diabetes of the young.

At present, the classification of genetic variants follows the guidelines of the American College of Medicals Genetics and uses a five-class score ([@bib10]). According to these criteria, FPLD4-associated *PLIN1* frameshift variants that disrupt protein function should be classified as "pathogenic." Laver *et al.* ([@bib6]) suggested that *PLIN1* null variants should not be reported as causative of lipodystrophy. Our study provides a set of arguments supporting the pathogenicity of several *PLIN1* frameshift variants. It is thus important to evaluate each of these variants carefully for genetic counseling. We would recommend detailed familial investigations, adipose tissue-focused examination, and careful follow-up of metabolic evolution in patients carrying such variants.
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